Testing a new drug for men with BRCA-related prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a BRCA1 or BRCA2 gene mutation (confirmed by a tumor tissue test).
- Your prostate cancer must be newly diagnosed as high-risk (localized but aggressive) OR have come back after surgery with high-risk features, but it must not have spread outside the pelvis.
- You will be receiving radiation therapy to the prostate (and possibly pelvis) along with hormone therapy (ADT) as part of your treatment plan.
- You must be in good overall health (able to perform daily activities) and have adequate organ and bone marrow function.
- You cannot have had previous chemotherapy (like docetaxel) or a PARP inhibitor, and you must not have a history of bleeding problems or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding a medicine called olaparib to radiation helps men with high-risk prostate cancer. You may receive radiation alone or radiation plus olaparib, and the study looks at whether the combination works better.
This study uses a special PET scan (FTT-PET) and a blood test (ctDNA) to see if they can predict how well PARP inhibitor therapy works in men with metastatic prostate cancer that has specific genetic mutations. It aims to improve treatment decisions by identifying which patients benefit most from these drugs.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.